Breast Cancer-targets And Therapy SCIE

國際簡稱：BREAST CANCER-TARGET 參考譯名：乳腺癌-靶點和治療

主要研究方向：ONCOLOGY 非預警期刊審稿周期： 16 Weeks

《乳腺癌-靶點和治療》(Breast Cancer-targets And Therapy)是一本由Dove Medical Press出版的以ONCOLOGY為研究特色的國際期刊，發(fā)表該領域相關的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領域相關理論、實踐和應用學科的最新發(fā)現(xiàn)，旨在促進該學科領域科學信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預警名單。

4區(qū) 中科院分區(qū)
Q2 JCR分區(qū)
75 年發(fā)文量
3.3 IF影響因子
開放是否OA
1 issue/year 出版周期
English 出版語言

"Breast Cancer: Targets and Therapy," with its open-access nature, provides a valuable resource for medical researchers, clinicians, and patients with breast cancer. The journal covers comprehensive research from basic biological mechanisms to clinical applications, committed to promoting innovation and progress in the field of breast cancer treatment.

The journal pays special attention to precision medicine and personalized treatment plans, emphasizing in-depth research on molecular targets of breast cancer and how to translate these research findings into effective clinical treatments. In addition, the journal encourages the publication of research on new drug development, drug sensitivity, resistance mechanisms, and new therapeutic technologies, aiming to provide more treatment options for patients with breast cancer.

[ 查看全部 ]

投稿咨詢加急咨詢

Breast Cancer-targets And Therapy期刊信息

ISSN：1179-1314
出版語言：English
是否OA：開放
E-ISSN：1179-1314
出版地區(qū)：United Kingdom
是否預警：否
出版商：Dove Medical Press
出版周期：1 issue/year
開源占比：0.9752
Gold OA文章占比：98.22%
OA被引用占比：1
出版國人文章占比：0.03
出版撤稿占比：
研究類文章占比：77.33%

Breast Cancer-targets And Therapy CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

4.1

0.933

1.009

學科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q3	203 / 404	49%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據(jù)是期刊最近4年（含計算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻數(shù)。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻數(shù)量注：文獻類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Breast Cancer-targets And Therapy中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫(yī)學	4區(qū)	ONCOLOGY 腫瘤學	4區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫(yī)學	4區(qū)	ONCOLOGY 腫瘤學	4區(qū)

Breast Cancer-targets And Therapy JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：ONCOLOGY	SCIE	Q2	118 / 322	63.5%

按JCI指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：ONCOLOGY	SCIE	Q3	186 / 322	42.39%

Breast Cancer-targets And Therapy歷年數(shù)據(jù)統(tǒng)計

影響因子

中科院分區(qū)

Breast Cancer-targets And Therapy中國學者發(fā)文選摘

1、Critical Evaluation of Secondary Cancer Risk After Breast Radiation Therapy with Hybrid Radiotherapy Techniques
Author: Zhang, Quanbin; Zeng, Yu; Peng, Yingying; Yu, Hui; Zhang, Shuxu; Wu, Shuyu

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 25-38. DOI: 10.2147/BCTT.S383369
2、An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC
Author: Zhang, Mengqi; Bao, Shengxian; Qiu, Guanhua; Liang, Jingchen; Wang, Qin; Zhu, Xiaoqi; Qin, Guchun; Liu, Junjie; Zhao, Chang

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 101-119. DOI: 10.2147/BCTT.S387793
3、Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review
Author: Wu, Jing; Jin, Yudi; Liu, Mei; Zhu, Ningsheng; Jing, Zhouhong; Zeng, Xiaohua

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 39-45. DOI: 10.2147/BCTT.S395944
4、Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
Author: Wang, Jin; Liao, Dongying; Zhang, Xuemin; Miao, Changhong; Chen, Kuang

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 281-294. DOI: 10.2147/BCTT.S407181
5、Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients
Author: Shen, Jun; Yan, Huanhuan; Yang, Congying; Lin, Haiyue; Li, Fan; Zhou, Jun

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 295-310. DOI: 10.2147/BCTT.S402109
6、Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
Author: Ma, Jing; Dong, Chao; Cao, Yan-Zhen; Ma, Bin-Lin

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 11-24. DOI: 10.2147/BCTT.S390017
7、The Prognostic Role of HuR Varies Between Different Subtypes of Breast Cancer Patients: Data Mining and Retrospective Analysis
Author: Liao, Yuqian; Liao, Yulu; Li, Jun; Li, Yong; Fan, Ying

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 135-146. DOI: 10.2147/BCTT.S395984
8、Optimized Radiomics Nomogram Based on Automated Breast Ultrasound System: A Potential Tool for Preoperative Prediction of Metastatic Lymph Node Burden in Breast Cancer
Author: Li, Ning; Song, Chao; Huang, Xian; Zhang, Hongjiang; Su, Juan; Yang, Lichun; He, Juhua; Cui, Guihua

Journal: BREAST CANCER-TARGETS AND THERAPY. 2023; Vol. 15, Issue , pp. 121-132. DOI: 10.2147/BCTT.S398300